$NLNK Recent Headlines 9 IPOs on tap; Angie's Li
Post# of 144482
Posted On: 12/11/2013 2:18:10 PM
$NLNK Recent Headlines
9 IPOs on tap; Angie's List, Delphi lead 1:11 p.m. Nov. 12, 2011 - MarketWatch.com
10-Q: NEWLINK GENETICS CORP 7:11 a.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
2013 Biotech Watchlist Update: Companies Climb And Crumble On Catalysts 10:48 a.m. Nov. 1, 2013 - Seeking Alpha
Jefferies Top Biotech Stocks to Buy 6:39 a.m. Oct. 14, 2013 - 247WallSt.com
4 Companies You Must Watch Regardless Of Market Performance 12:15 p.m. Oct. 9, 2013 - Seeking Alpha
NewLink Genetics Corp (NLNK) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape 7:33 a.m. Sept. 24, 2013 - Zacks.com
Investors are Betting Against NewLink Genetics Corp (NLNK), Should You? - Tale of the Tape 7:15 a.m. Sept. 16, 2013 - Zacks.com
NewLink Genetics Corporation Offers a Risky Way to Generate Income 6:21 p.m. Sept. 11, 2013 - GuruFocus.com
4 Biotechs With Catalysts Looming 6:59 a.m. Sept. 4, 2013 - Seeking Alpha
10-Q: NEWLINK GENETICS CORP 11:42 a.m. Aug. 8, 2013 - Edgar Online - (EDG = 10Q, 10K)
6 Oncology-Focused Biotech Growth Engines: Mara Goldstein 5:01 p.m. Aug. 2, 2013 - Seeking Alpha
5 Speculative Biotech Stocks With Catalysts Pending: Revisited 10:58 a.m. July 17, 2013 - Seeking Alpha
UPDATE: Jefferies Initiates NewLink Genetics at Buy on Immunotherapy Platform Upside 6:39 a.m. June 14, 2013 - benzinga.com
Why Did Immunotherapy Pioneer NewLink Genetics Reach A 52-Week High? 10:41 a.m. June 10, 2013 - Seeking Alpha
NewLink Genetics Presents Positive Phase 2 Tergenpumatucel-L Non-Small Cell Lung Cancer Data 10:05 a.m. June 1, 2013 - benzinga.com
NewLink Genetics: Looking To Join The Industry's Largest Movers 4:51 a.m. April 29, 2013 - Seeking Alpha
NewLink Genetics Begins Phase 2 Indoximod Trial for Treatment of Metastatic Breast Cancer 5:03 a.m. April 2, 2013 - benzinga.com
3 Immunotherapy Companies That Have Learned Their Lessons Well 3:29 a.m. March 18, 2013 - Seeking Alpha
A Comprehensive Look At Immunotherapy - Part 2 10:04 a.m. March 4, 2013 - Seeking Alpha
UPDATE: Stifel Nicolaus Raises PT to $21 on NewLink Genetics on Accelerated Patient Enrollment 11:46 a.m. March 1, 2013 - benzinga.com
NewLink Genetics' CEO Discusses Q4 2012 Results - Earnings Call Transcript 3:39 p.m. Feb. 28, 2013 - Seeking Alpha
NewLink Genetics Initiates Phase 1 Clinical Trial of NLG919, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy 7:01 a.m. Dec. 10, 2013 - Marketwire
/ CORRECTION - NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference 12:11 p.m. Dec. 5, 2013 - Marketwire
NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference 7:01 a.m. Dec. 5, 2013 - Marketwire
NewLink Genetics Corporation Reports Third Quarter 2013 Financial Results 7:01 a.m. Nov. 12, 2013 - Marketwire
NewLink Genetics to Present at the Credit Suisse 2013 Healthcare Conference 4:30 p.m. Nov. 6, 2013 - Marketwire
Mentor Capital Cancer Immunotherapy Index Up 100% in 2013 7:03 a.m. Oct. 16, 2013 - BusinessWire
Positive Results, Close of Public Offerings, Grants, Data Presentations and Partnerships - Research Report on Lexicon, Sangamo Biosciences, Immunomedics, NewLink Genetics, and Pacific Biosciences 7:00 a.m. Oct. 4, 2013 - PR Newswire
NewLink Genetics Completes Patient Enrollment in Phase 3 Algenpantucel-L (IMPRESS) Clinical Study 6:16 a.m. Sept. 17, 2013 - ACCESSWIRE
NewLink Genetics Completes Patient Enrollment in Phase 3 Algenpantucel-L (IMPRESS) Clinical Study 6:06 a.m. Sept. 17, 2013 - ACCESSWIRE
NewLink Genetics to Present Data on Cancer Immunotherapy Programs at the 2013 European Cancer Congress 3:21 p.m. Sept. 12, 2013 - ACCESSWIRE
NewLink Genetics to Present at September Financial Conferences 6:01 a.m. Sept. 5, 2013 - Marketwire
NewLink Genetics Corporation Reports Second Quarter 2013 Financial Results 6:01 a.m. Aug. 7, 2013 - Marketwire
Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013 12:49 p.m. July 19, 2013 - BusinessWire
New Research Grants, Product Launches, and Positive Clinical Study Results - Research Report on Boston Scientific, Cooper, Arena Pharmaceuticals, Apricus Biosciences, and NewLink Genetics 7:00 a.m. June 13, 2013 - PR Newswire
NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic Cancer 6:30 a.m. June 3, 2013 - PR Newswire
NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting 6:30 a.m. June 3, 2013 - PR Newswire
NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting 8:00 a.m. June 1, 2013 - PR Newswire
NewLink Genetics to Present at the Jefferies 2013 Healthcare Conference 7:00 a.m. May 29, 2013 - PR Newswire
NewLink Genetics to Be Added to NASDAQ Biotechnology Index 7:10 a.m. May 16, 2013 - Marketwire
NewLink Genetics to Present Data on Cancer Immunotherapy Programs at the ASCO 2013 Annual Meeting 7:07 a.m. May 16, 2013 - Marketwire
9 IPOs on tap; Angie's List, Delphi lead 1:11 p.m. Nov. 12, 2011 - MarketWatch.com
10-Q: NEWLINK GENETICS CORP 7:11 a.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
2013 Biotech Watchlist Update: Companies Climb And Crumble On Catalysts 10:48 a.m. Nov. 1, 2013 - Seeking Alpha
Jefferies Top Biotech Stocks to Buy 6:39 a.m. Oct. 14, 2013 - 247WallSt.com
4 Companies You Must Watch Regardless Of Market Performance 12:15 p.m. Oct. 9, 2013 - Seeking Alpha
NewLink Genetics Corp (NLNK) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape 7:33 a.m. Sept. 24, 2013 - Zacks.com
Investors are Betting Against NewLink Genetics Corp (NLNK), Should You? - Tale of the Tape 7:15 a.m. Sept. 16, 2013 - Zacks.com
NewLink Genetics Corporation Offers a Risky Way to Generate Income 6:21 p.m. Sept. 11, 2013 - GuruFocus.com
4 Biotechs With Catalysts Looming 6:59 a.m. Sept. 4, 2013 - Seeking Alpha
10-Q: NEWLINK GENETICS CORP 11:42 a.m. Aug. 8, 2013 - Edgar Online - (EDG = 10Q, 10K)
6 Oncology-Focused Biotech Growth Engines: Mara Goldstein 5:01 p.m. Aug. 2, 2013 - Seeking Alpha
5 Speculative Biotech Stocks With Catalysts Pending: Revisited 10:58 a.m. July 17, 2013 - Seeking Alpha
UPDATE: Jefferies Initiates NewLink Genetics at Buy on Immunotherapy Platform Upside 6:39 a.m. June 14, 2013 - benzinga.com
Why Did Immunotherapy Pioneer NewLink Genetics Reach A 52-Week High? 10:41 a.m. June 10, 2013 - Seeking Alpha
NewLink Genetics Presents Positive Phase 2 Tergenpumatucel-L Non-Small Cell Lung Cancer Data 10:05 a.m. June 1, 2013 - benzinga.com
NewLink Genetics: Looking To Join The Industry's Largest Movers 4:51 a.m. April 29, 2013 - Seeking Alpha
NewLink Genetics Begins Phase 2 Indoximod Trial for Treatment of Metastatic Breast Cancer 5:03 a.m. April 2, 2013 - benzinga.com
3 Immunotherapy Companies That Have Learned Their Lessons Well 3:29 a.m. March 18, 2013 - Seeking Alpha
A Comprehensive Look At Immunotherapy - Part 2 10:04 a.m. March 4, 2013 - Seeking Alpha
UPDATE: Stifel Nicolaus Raises PT to $21 on NewLink Genetics on Accelerated Patient Enrollment 11:46 a.m. March 1, 2013 - benzinga.com
NewLink Genetics' CEO Discusses Q4 2012 Results - Earnings Call Transcript 3:39 p.m. Feb. 28, 2013 - Seeking Alpha
NewLink Genetics Initiates Phase 1 Clinical Trial of NLG919, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy 7:01 a.m. Dec. 10, 2013 - Marketwire
/ CORRECTION - NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference 12:11 p.m. Dec. 5, 2013 - Marketwire
NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference 7:01 a.m. Dec. 5, 2013 - Marketwire
NewLink Genetics Corporation Reports Third Quarter 2013 Financial Results 7:01 a.m. Nov. 12, 2013 - Marketwire
NewLink Genetics to Present at the Credit Suisse 2013 Healthcare Conference 4:30 p.m. Nov. 6, 2013 - Marketwire
Mentor Capital Cancer Immunotherapy Index Up 100% in 2013 7:03 a.m. Oct. 16, 2013 - BusinessWire
Positive Results, Close of Public Offerings, Grants, Data Presentations and Partnerships - Research Report on Lexicon, Sangamo Biosciences, Immunomedics, NewLink Genetics, and Pacific Biosciences 7:00 a.m. Oct. 4, 2013 - PR Newswire
NewLink Genetics Completes Patient Enrollment in Phase 3 Algenpantucel-L (IMPRESS) Clinical Study 6:16 a.m. Sept. 17, 2013 - ACCESSWIRE
NewLink Genetics Completes Patient Enrollment in Phase 3 Algenpantucel-L (IMPRESS) Clinical Study 6:06 a.m. Sept. 17, 2013 - ACCESSWIRE
NewLink Genetics to Present Data on Cancer Immunotherapy Programs at the 2013 European Cancer Congress 3:21 p.m. Sept. 12, 2013 - ACCESSWIRE
NewLink Genetics to Present at September Financial Conferences 6:01 a.m. Sept. 5, 2013 - Marketwire
NewLink Genetics Corporation Reports Second Quarter 2013 Financial Results 6:01 a.m. Aug. 7, 2013 - Marketwire
Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013 12:49 p.m. July 19, 2013 - BusinessWire
New Research Grants, Product Launches, and Positive Clinical Study Results - Research Report on Boston Scientific, Cooper, Arena Pharmaceuticals, Apricus Biosciences, and NewLink Genetics 7:00 a.m. June 13, 2013 - PR Newswire
NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic Cancer 6:30 a.m. June 3, 2013 - PR Newswire
NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting 6:30 a.m. June 3, 2013 - PR Newswire
NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting 8:00 a.m. June 1, 2013 - PR Newswire
NewLink Genetics to Present at the Jefferies 2013 Healthcare Conference 7:00 a.m. May 29, 2013 - PR Newswire
NewLink Genetics to Be Added to NASDAQ Biotechnology Index 7:10 a.m. May 16, 2013 - Marketwire
NewLink Genetics to Present Data on Cancer Immunotherapy Programs at the ASCO 2013 Annual Meeting 7:07 a.m. May 16, 2013 - Marketwire
(0)
(0)Scroll down for more posts ▼